Adamas Pharma (ADMS): Strong Balance Sheet & Cost Containment in 3Q:16 - Mizuho

November 7, 2016 7:14 AM EST
Get Alerts ADMS Hot Sheet
Price: $14.99 -4.83%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 30 | New: 23
Trade ADMS Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on shares of Adamas Pharmaceuticals (NASDAQ: ADMS) after announcing a bottom line "beat" driven by reduced spending.

The company also disclosed a $200M shelf filing, and a potential $22.3M secondary offering at $13.91, which should bolster its balance sheet in the unlikely scenario the company decided to go it alone rather than be acquired. The analyst still views ADMS as a likely takeout target in 2017 and reiterated her $26 PT.

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $13.93 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Earnings

Related Entities

Irina Koffler

Add Your Comment